Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors’ Health Network

International Journal of Drug Policy

Volumn 47, Issue , 2017, Pages 216-220

  Morris, Leith ^a   Smirnov, Andrew ^a   Kvassay, Amanda ^b   Leslie, Ellen ^a   Kavanagh, Rebecca ^b   Alexander, Nik ^b   Davey, Geoff ^b   Williams, Owain ^a   Gilks, Charles ^a   Najman, Jake ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Queensland Injectors Health Network   (Australia)

Author keywords

Antiviral therapy; Hepatitis C; Injecting drug use; People who inject drugs; Treatment outcomes

Indexed keywords

ANTIVIRUS AGENT; DACLATASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SOFOSBUVIR;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COMMUNITY CARE; CONTROLLED STUDY; FEMALE; HARM REDUCTION; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS C; HUMAN; INTEGRATED HEALTH CARE SYSTEM; INTENTION TO TREAT ANALYSIS; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING; AGED; COMPLICATION; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; QUEENSLAND; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; COMMUNITY HEALTH SERVICES; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; QUEENSLAND; SUBSTANCE ABUSE, INTRAVENOUS; SUSTAINED VIROLOGIC RESPONSE; YOUNG ADULT;

EID: 85021824854     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.05.056     Document Type: Article

References (14)

1. Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.-S., Muljono, D.H., Razavi, H., Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology & Hepatology 2:3 (2017), 161–176, 10.1016/S2468-1253(16)30181-9.
2. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., on behalf of the, C-EDGE CO-STAR Study Group, Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial. Annals of Internal Medicine 165:9 (2016), 625–634, 10.7326/m16-0816.
3. Grebely, J., Alavi, M., Micallef, M., Dunlop, A.J., Balcomb, A.C., Phung, N., Dore, G.J., Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study. Addiction (Abingdon, England) 111:2 (2016), 311–319, 10.1111/add.13197.
4. Grebely, J., Dore, G.J., Zeuzem, S., Aspinall, R.J., Fox, R., Han, L., Feld, J.J., Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials. Clinical Infectious Diseases 63:11 (2016), 1479–1481, 10.1093/cid/ciw579.
5. Grebely, J., Mauss, S., Brown, A., Bronowicki, J.P., Puoti, M., Wyles, D., Dore, G.J., Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of phase 3 ION trials. Clinical Infectious Diseases 63:11 (2016), 1405–1411, 10.1093/cid/ciw580.
6. Iversen, J., Maher, L., Australian NSP Survey. Prevalence of HIV, HCV and injecting and sexual behaviour among Needle and Syringe Program attendees: 20 Year National Data Report 1995-2014., 2015.
7. Lalezari, J., Sullivan, J.G., Varunok, P., Galen, E., Kowdley, K.V., Rustgi, V., Cohen, D.E., Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology 63:2 (2015), 364–369, 10.1016/j.jhep.2015.03.029.
8. Litwin, A.H., Soloway, I.J., Cockerham-Colas, L., Reynoso, S., Heo, M., Tenore, C., Roose, R.J., Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. International Journal of Drug Policy 26:10 (2015), 1014–1019, 10.1016/j.drugpo.2015.08.008.
9. Mason, K., Dodd, Z., Guyton, M., Tookey, P., Lettner, B., Matelski, J., Powis, J., Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence amongst people with a history of drug use at a community-based program in Toronto, Canada. International Journal of Drug Policy 47 (2017), 202–208.
10. Mehta, S.H., Genberg, B.L., Astemborski, J., Kavasery, R., Kirk, G.D., Vlahov, D., Thomas, D.L., Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health 33:3 (2008), 126–133, 10.1007/s10900-007-9083-3.
11. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., Degenhardt, L., Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. The Lancet 378:9791 (2011), 571–583, 10.1016/s0140-6736(11)61097-0.
12. Razavi, H., Waked, I., Sarrazin, C., Myers, R.P., Idilman, R., Calinas, F., Estes, C., The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis 21:Suppl. 1 (2014), 34–59, 10.1111/jvh.12248.
13. Read, P., Lothian, R., Chronister, K.J., Gilliver, R., Kearley, J., Dore, G.J., van Beek, I., Delivering direct acting antiviral therapy for hepatitis c to highly marginalised and current drug injecting populations in a targeted primary health care setting. International Journal of Drug Policy 47 (2017), 209–215.
14. StataCorp, Stata statistical software: Release 14. 2015, StataCorp LP, College Station, TX.